-
Dabrafenib
API Nomen Indicium Innovator Exitus patentibus Date (US) Dabrafenib -
Aprocitentan
API Nomen Indicium Innovator Exitus patentibus Date (US) Aprocitentan -
Etrasimod
API Nomen Indicium Innovator Exitus patentibus Date (US) Etrasimod Ulceratuve Colitis(UC) Arena (Pfizer) Mar.05,2030 -
Tirzepatide
API Nomen Indicium Innovator Exitus patentibus Date (US) Tirzepatide Typus II diabete, pondus amittere Eli Lilly Jan.05,2036 -
Semaglutide
API Nomen Indicium Innovator Exitus patentibus Date (US) Semaglutide Type2 diabete, pondus amittere Novo Nordisk Dec.05,2031 -
Oteseconazole
API Nomen Indicium Innovator Exitus patentibus Date (US) Oteseconazole Redigendum incidentiae rate of recurrens vulvovaginalis candidiasis
MycoviaPharmaceuticals Apr.22,2031 -
Finerenone
API Nomen Indicium Innovator Exitus patentibus Date (US) Finerenone Diabetic Nephropathia Bayer Apr.12,2029 -
Vibegron
API Nomen Indicium Innovator Exitus patentibus Date (US) Vibegron OAB Urovant Dec.01,2030 -
Capivasertib
API Nomen Indicium Innovator Exitus patentibus Date (US) Capivasertib pectus cancer AstraZeneca Mar.10.2030 -
Resmetirom
API Nomen Indicium Innovator Exitus patentibus Date (US) Resmetirom NASH Roche Sep.12,2026 -
Darolutamide
API Nomen Indicium Innovator Exitus patentibus Date (US) Darolutamide prostatica cancer curatio Bayer Mar -
Upadacitinib
API Nomen Indicium Innovator Exitus patentibus Date (US) Upadacitinib Dermatitis atopic ABBVIE INC Dec.01,2030